Skip to content

Application of Objective Indicators Based on Mobile Technology in Clinical Evaluation of Depression

Application of Objective Indicators Based on Mobile Technology in Clinical Evaluation of Depression

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000031719
Enrollment
Unknown
Registered
2020-04-08
Start date
2020-04-08
Completion date
Unknown
Last updated
2020-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Interventions

case series:Escitalopram

Sponsors

Beijing Anding Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Out-patient patients aged 18 ~ 65 (including 18 and 65 years old), regardless of gender; 2. Comply with the diagnostic criteria for major depressive disorder (MINI5.0.0) of the diagnostic and statistical manual of mental disorders (dsm-iv), with no psychotic symptoms; 3. This episode has not been treated with antidepressant system or no antidepressant treatment in the past 14 days; 4. Primary school education or above, able to understand the content of the scale; 5. Able to use an android smartphone and wear a smart bracelet as required; 6. Patient signs the informed consent.

Exclusion criteria

Exclusion criteria: 1. Previous clear manic or hypomanic episodes; 2. Previous diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder and mental disorders associated with other diseases; 3. Patients with previous alcohol and drug dependence and acute poisoning history; 4. Patients who currently have a serious risk of suicide; 5. Have independent sleep disturbances (eg, obstructive sleep apnea, narcolepsy, bruxism, periodic limb movement disorders, restless legs, and other sleep behavior abnormalities); 6. At present, there are diseases that seriously affect heart rate and respiratory monitoring, such as acute onset of chronic obstructive pulmonary disease, acute onset of asthma, sinus tachycardia, sinus bradycardia, arrhythmia and other diseases; 7. Patients who have been previously ineffective or allergic to escitalopram; 8. At present, some researchers with severe physical diseases consider it inappropriate to be enrolled in this study.

Design outcomes

Primary

MeasureTime frame
HAMD-17 total score and item score;HAMA total score and item score;PHQ-9 total score and item score;sleep duration;body temperature;heart rate;step number;the variety of motion track;step number;smartphone usage behavior;

Countries

China

Contacts

Public ContactFeng Lei

Beijing Anding Hospital Capital Medical University

flxlm@126.com+86 15810910218

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026